Home » Blog » The Cost of Care in 2014… and a Walmart Surprise

The Cost of Care in 2014… and a Walmart Surprise


IP Blog | Dave Melin | January 12, 2014

BioBlogWeeklyThis week in healthcare, IP takes a walk on the financial side — of the healthcare and biopharmaceutical industry in the United States.

Surprise! Walmart health plan is cheaper, offers more coverage than Obamacare

According to a comparison by the Washington Examiner between coverage provided by a Walmart plan and an ACA plan, they found that Walmart’s plan (managed nationally by Blue Cross Blue Shield) “is more affordable and provides significantly better access to high-quality medical care than Obamacare.”

A prosperous new year for pharma? Let’s check the tea leaves

What will 2014 hold for the U.S. pharmaceutical industry? According to this author, growing pricing pressure and cost battles. See what some leading pharma companies are doing to plan for success in 2014.

9 Drivers of High Healthcare Costs in the U.S.

According to the State Health Care Cost Containment Commission’s latest report, here are the “nine primary drivers” of high healthcare costs in the U.S.

ASCO Physician Payment Reform Education Series Part 5: A Proposal for Patient-Centered Payment Reform

Check out the latest installment in ASCO’s multi-part series on physician payment reform. In this the fifth part, ASCO outlines “a new framework for oncology reimbursement that recognizes and rewards high quality, high value care for patients with cancer.”

Cracking The Code On Health Care Costs: What The States Can Do

Also from the State Health Care Cost Containment Commission, here are some major policy levers available to states as well as seven recommendations for how to craft a comprehensive approach to make the healthcare market work, regardless of the ACA’s status.

How Much Does A New Hip Cost? Even The Surgeon Doesn’t Know

Although Medicare “spends about $20 billion each year on implanted medical devices”, orthopedic surgeons “were only able to correctly estimate the cost of a device 21 percent of the time” according to a recent survey published in Health Affairs. The problem, says the study’s author, is a lack of price transparency across the industry.

Want more up-to-date biopharma info? Follow us on Twitter @innovpartners.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *